[go: up one dir, main page]

MX2021011913A - Composiciones de virus inactivado y formulaciones de vacunas contra el zika. - Google Patents

Composiciones de virus inactivado y formulaciones de vacunas contra el zika.

Info

Publication number
MX2021011913A
MX2021011913A MX2021011913A MX2021011913A MX2021011913A MX 2021011913 A MX2021011913 A MX 2021011913A MX 2021011913 A MX2021011913 A MX 2021011913A MX 2021011913 A MX2021011913 A MX 2021011913A MX 2021011913 A MX2021011913 A MX 2021011913A
Authority
MX
Mexico
Prior art keywords
inactivated virus
vaccine formulations
virus compositions
zika vaccine
pharmaceutically acceptable
Prior art date
Application number
MX2021011913A
Other languages
English (en)
Inventor
Michael Johnson
Sushma Kommareddy
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2021011913A publication Critical patent/MX2021011913A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención hace referencia a una composición líquida de virus inactivado que comprende: un virus del Zika completo e inactivado, al menos un tampón aceptable desde un punto de vista farmacéutico con una concentración de al menos aproximadamente 6.5 mM, y opcionalmente un poliol, en la que dicho al menos un tampón aceptable desde un punto de vista farmacéutico no comprende iones fosfato y vacunas derivadas de estos.
MX2021011913A 2019-05-08 2020-04-08 Composiciones de virus inactivado y formulaciones de vacunas contra el zika. MX2021011913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962845024P 2019-05-08 2019-05-08
PCT/US2020/027154 WO2020226831A1 (en) 2019-05-08 2020-04-08 Inactivated virus compositions and zika vaccine formulations

Publications (1)

Publication Number Publication Date
MX2021011913A true MX2021011913A (es) 2021-12-15

Family

ID=70465537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011913A MX2021011913A (es) 2019-05-08 2020-04-08 Composiciones de virus inactivado y formulaciones de vacunas contra el zika.

Country Status (14)

Country Link
US (1) US20220211836A1 (es)
EP (1) EP3965811A1 (es)
JP (1) JP2022533550A (es)
KR (1) KR20220007077A (es)
CN (1) CN113939311A (es)
AR (1) AR118881A1 (es)
AU (1) AU2020269164B2 (es)
BR (1) BR112021019845A2 (es)
CA (1) CA3137652A1 (es)
IL (1) IL288002A (es)
MX (1) MX2021011913A (es)
SG (1) SG11202110975XA (es)
TW (1) TW202108168A (es)
WO (1) WO2020226831A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081586A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN111601885B (zh) 2017-11-30 2025-01-07 武田疫苗股份有限公司 用于将寨卡病毒灭活的方法和相关方法
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
JP2008512443A (ja) 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
US8865184B2 (en) * 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
BR112018000862A2 (pt) * 2015-07-16 2018-09-11 Bharat Biotech International Limited composições de vacina
JP6949027B2 (ja) * 2015-12-23 2021-10-20 バルネバ オーストリア ジーエムビーエイチ ジカウイルスワクチン
CN105749268B (zh) * 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
US11033615B2 (en) * 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
CN109081868B (zh) * 2017-06-14 2022-06-24 中国科学院上海巴斯德研究所 靶向寨卡病毒包膜蛋白保守表位的单克隆抗体及其应用
CA3081586A1 (en) * 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN111601885B (zh) * 2017-11-30 2025-01-07 武田疫苗股份有限公司 用于将寨卡病毒灭活的方法和相关方法
CN108187036A (zh) * 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 一种寨卡病毒与乙脑病毒联合灭活疫苗

Also Published As

Publication number Publication date
CN113939311A (zh) 2022-01-14
WO2020226831A1 (en) 2020-11-12
CA3137652A1 (en) 2020-11-12
BR112021019845A2 (pt) 2022-02-15
SG11202110975XA (en) 2021-10-28
AR118881A1 (es) 2021-11-10
KR20220007077A (ko) 2022-01-18
TW202108168A (zh) 2021-03-01
IL288002A (en) 2022-01-01
JP2022533550A (ja) 2022-07-25
AU2020269164A1 (en) 2021-11-25
AU2020269164B2 (en) 2024-04-04
EP3965811A1 (en) 2022-03-16
US20220211836A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
MX2021011913A (es) Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
PH12020550051B1 (en) Glp-1 compositions and uses thereof
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MY199422A (en) Methods of manufacturing an immunogenic composition comprising a recombinant protein
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
MX2021002586A (es) Dosis unitaria de vacuna contra el dengue y administracion de esta.
GEP20237539B (en) Formulations of dengue virus vaccine compositions
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
EA201390812A1 (ru) Лиофилизированные вирусные составы
WO2017156511A8 (en) Live attenuated zika virus vaccine
PH12019501320A1 (en) Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
PH12021550441A1 (en) Modified pedv spike protein
PH12018500675A1 (en) Stable live attenuated recombinant dengue vaccine
MX2019012620A (es) Composiciones de vacunas.
MX2017012389A (es) Vacuna del virus de la parotiditis recombinante jeryl lynn2.
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
PH12020551618A1 (en) Erenumab compositions and uses thereof
MY153290A (en) Multivalent avian influenza vaccines
BR112021023319A2 (pt) Vetor viral
BR112014023398A2 (pt) vírus da doença de marek modidicado e vacinas feitas do mesmo